| Dr Chandni K Anand, MD | |
|
831 S Broadway, Minot, ND 58701-4636 | |
| (701) 857-7986 | |
| (701) 857-7979 |
| Full Name | Dr Chandni K Anand |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 831 S Broadway, Minot, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518908862 | NPI | - | NPPES |
| 009382300 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | ME116650 (Florida) | Secondary |
| 207R00000X | Internal Medicine | 22950 (Nevada) | Secondary |
| 207R00000X | Internal Medicine | 16192 (North Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Las Vegas Medical Group Llc | 6800118522 | 43 |
News Archive
A study in today's issue of the Annals of Internal Medicine reports a miss rate of approximately 10 percent for large (>5mm) precancerous polyps during conventional colonoscopy.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.
One member of a large protein family that is known to stop the spread of bacterial infections by prompting infected human cells to self-destruct appears to kill the infectious bacteria instead, a new study led by UT Southwestern scientists shows.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 4 days ago
| Entity Name | Las Vegas Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447656988 PECOS PAC ID: 6800118522 Enrollment ID: O20141209001376 |
News Archive
A study in today's issue of the Annals of Internal Medicine reports a miss rate of approximately 10 percent for large (>5mm) precancerous polyps during conventional colonoscopy.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.
One member of a large protein family that is known to stop the spread of bacterial infections by prompting infected human cells to self-destruct appears to kill the infectious bacteria instead, a new study led by UT Southwestern scientists shows.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chandni K Anand, MD Po Box 5010, Minot, ND 58702-5010 Ph: (701) 857-5000 | Dr Chandni K Anand, MD 831 S Broadway, Minot, ND 58701-4636 Ph: (701) 857-7986 |
News Archive
A study in today's issue of the Annals of Internal Medicine reports a miss rate of approximately 10 percent for large (>5mm) precancerous polyps during conventional colonoscopy.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.
One member of a large protein family that is known to stop the spread of bacterial infections by prompting infected human cells to self-destruct appears to kill the infectious bacteria instead, a new study led by UT Southwestern scientists shows.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 4 days ago
Nasser Saffarian, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000 | |
Bruce B Swenson, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 Burdick Expy E, Minot, ND 58701 Phone: 701-857-7998 Fax: 701-857-7342 | |
John E Sheehan, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 831 S Broadway, Minot, ND 58701 Phone: 701-857-5853 Fax: 701-857-5244 | |
Moayed Ibrahim, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 831 S Broadway, Minot, ND 58701 Phone: 701-857-3534 Fax: 701-857-5171 | |
Disa L.g. Awah, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Burdick Expy E, Minot, ND 58701 Phone: 701-857-7969 Fax: 701-857-7957 | |
Dr. Ashley Sarasan, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 305 8th Ave Ne, Minot, ND 58703 Phone: 701-857-5800 | |
Erdal Diri, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 37th Ave Sw, Minot, ND 58701 Phone: 701-857-5000 |